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ABSTRACT: Background: The PD MED study
reported small but persistent benefits in patient-rated
mobility scores and quality of life from initiating ther-
apy with levodopa compared with levodopa-sparing
therapies in early Parkinson’s disease (PD).
Objectives: The objective was to estimate the cost-
effectiveness of levodopa-sparing therapy (dopamine
agonists or monoamine oxidase type B inhibitors com-
pared with levodopa alone.
Methods: PD MED is a pragmatic, open-label randomized,
controlled trial in which patients newly diagnosed with PD
were randomly assigned between levodopa-sparing ther-
apy (dopamine agonists or monoamine oxidase type B
inhibitors ) and levodopa alone. Mean quality-adjusted life-
years and costs were calculated for each participant. Differ-
ences in mean quality-adjusted life-years and costs
between levodopa and levodopa-sparing therapies and
between dopamine agonists and monoamine oxidase type
B inhibitors were estimated using linear regression.
Results: Over a mean observation period of 4 years, levo-
dopa was associated with significantly higher quality-
adjusted life-years (difference, 0.18; 95% CI, 0.05–0.30;
P < 0.01) and lower mean costs (£3390; £2671–£4109;
P < 0.01) than levodopa-sparing therapies, the difference in
costs driven by the higher costs of levodopa-sparing thera-
pies. There were no significant differences in the costs of
inpatient, social care, and institutional care between arms.
There was no significant difference in quality-adjusted life-
years between those allocated dopamine agonists and
monoamine oxidase type B inhibitors (0.02; −0.17 to 0.13 in
favor of dopamine agonists; P = 0.81); however costs were
significantly lower for those allocated monoamine oxidase
type B inhibitors (£2321; £1628–£3015; P < 0.01) because
of the higher costs of dopamine agonists. There were no
significant differences between arms for other costs.
Conclusions: Initial treatment with levodopa is highly
cost-effective compared with levodopa-sparing thera-
pies. Monoamine oxidase type B inhibitors, as initial
levodopa-sparing therapy was more cost-effective, with
similar quality-adjusted life-years but lower costs than
dopamine agonists. © 2021 The Authors. Movement Dis-
orders published by Wiley Periodicals LLC on behalf of
International Parkinson and Movement Disorder Society
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Parkinson’s disease (PD)1 is a progressive neurological
disorder associated with motor disabilities including
tremor, rigidity, slowness, and postural disturbance. In the
United Kingdom, 8000 new cases are diagnosed every year,
and more than 100,000 people are living with PD.2,3
Levodopa is the most commonly used class of drug in the
treatment of early-stage PD, providing good symptomatic
relief for most patients and possibly improving survival.4,5
However, after a few years of treatment, motor complica-
tions (“wearing-off,” “on–off,” fluctuations, and dyskinesia)
often develop.6 Levodopa-sparing therapies such as dopa-
mine agonists (DAs) andmonoamine oxidase type B inhibi-
tors (MAOBIs) have been used, either alone or with
reduced doses of levodopa, in an attempt to delay the onset
of motor complications. Although, motor complications
are seen less frequently with levodopa-sparing therapies,
nonmotor side effects such as nausea, hallucinations,
edema, and sleep disturbance are more frequent with DAs
thanwith levodopa.7,8
The PD MED trial demonstrated that the overall bal-
ance of benefits and risks favors levodopa over
levodopa-sparing therapies with better patient-rated
Health-Related Quality of Life (HRQoL) in both the
short and long term. There were no significant differ-
ences in the rate of dementia, institutionalization, or
mortality.1 In cases for which levodopa-sparing therapy
is deemed appropriate, DAs have traditionally been pre-
ferred to MAOBIs, which are perceived as less effective.
However, in PD MED, patient-rated HRQoL was mar-
ginally better for those allocated MAOBIs.1 We have
extended these analyses by reporting a cost-utility anal-
ysis of levodopa versus levodopa-sparing therapies, and




The design of PD MED, a pragmatic, open-label ran-
domized trial, data collection instruments, and the main
clinical results have been reported in detail in the trial
protocol (http://www.isrctn.com/ISRCTN69812316)
and published in a clinical article.1 Individuals diag-
nosed with idiopathic PD9 were eligible if they were
previously untreated or had been treated for less than
6 months with dopaminergic drugs and if there were
uncertainty about which class of drug to use. Exclu-
sion criteria included dementia and the inability to
complete trial questionnaires. Ethical approval was
provided by the West Midlands Research Ethics Com-
mittee, local approval was obtained at each participat-
ing center, and all patients gave written informed
consent.
Patients were randomly assigned (1:1:1) to receive
levodopa, DA, or MAOBI. Either MAOBI or levodopa
could be omitted from the randomization if considered
inappropriate for a particular patient. Patients and
investigators were not masked to group assignment.
Investigators were allowed to start open-label treatment
with whichever drug they preferred within the allocated
class and to titrate the dose of levodopa and DA within
the bounds of the product license. If symptoms were
not controlled by the standard dose of MAOBI or the
maximum tolerated dose of DA, investigators could add
levodopa as needed. Otherwise, adding or switching to a
new drug was only permissible if patients’ symptoms
were not adequately controlled or for adverse effects.
Resource Use Information
The economic analysis was performed from a health
and personal social services perspective (PSS), as rec-
ommended by the National Institute for Health and
Care Excellence (NICE) in the United Kingdom.10
Information on patients’ use of drugs — type of drug
and dose — was completed by clinicians at annual
follow-up visits. If institutionalization occurred, the
type of care (residential or nursing) and the date were
recorded on the annual follow-up form, alongside
information on whether the patient developed dementia
or motor complications. Other health and PSS resource
use was self-reported by participants and collected at
annual intervals using a short questionnaire. This
recorded primary care and outpatient use (contacts
with general practitioners, nurse practitioner,
Parkinson’s disease nurses, health visitors, social
workers, physiotherapists, occupational therapists,
speech/language therapists, day hospitals, and neurol-
ogy outpatient departments), hospital stays and respite
care, and personal social services (home care/home
help, meals on wheels, day care, luncheon clubs, sitting
services, and night care). Unit costs were attached to
resource use volumes using UK 2011 prices, and both
costs and benefits were discounted at an annual rate of
3.5%, consistent with NICE guidance.10 Unit costs for
all resource items are presented in Table S1.
Health-Related Quality of Life
Health-Related Quality of Life (HRQoL) was esti-
mated using the EuroQol EQ-5D 3-level question-
naire.10,11 EQ-5D utilities were calculated by applying
the UK value set,12 with health state valuations ranging
from −0.596 to 1, where 1 represents perfect health,
0 is death, and negative values are health states consid-
ered worse than death. EQ-5D questionnaires were dis-
tributed to participants for self-completion at baseline,
6 months, 12 months, and annually thereafter.
Statistical Analysis
Two comparisons were made: (1) levodopa was com-
pared with levodopa-sparing therapies, incorporating
2 Movement Disorders, 2021






































































































































































































































































































































































































































































































































































































































































































































































































Movement Disorders, 2021 3
D O P A M I N E A G O N I S T S A N D M O N O A M I N E O X I D A S E B I N H I B I T O R S
information from those randomized among all 3 treat-
ments and those randomized between only levodopa
and DA, and (2) DA was compared with MAOBIs, uti-
lizing information from those randomized among all
3 treatments and those randomized between only DAs
and MAOBIs.
A small number of individuals recruited from outside
the United Kingdom were excluded from analysis.
Aggregated QALYs and costs were estimated for each
trial participant up to 7 years from randomization or
death if earlier. QALYs for each individual were
estimated using the area under the curve approach with
linear interpolation between times.13 Total costs were
calculated by first comparing costs by treatment arm
within each resource use category, class of drugs, and
institutionalization status, then excluding components
of cost for which there was no evidence of difference
between arms, and finally, summing the remaining
components.
Incremental costs and QALYs were calculated for
each comparison within a linear regression framework,
adjusting QALYs for baseline levels.14 The probability
of being cost-effective at a range of commonly accepted
UK threshold values for an incremental QALY was esti-
mated by resampling the patient population 2000 times
using bootstrapping with replacement to generate a
joint distribution of cost-effect pairs. Cost-effectiveness
was calculated for each iteration, and the proportion of
iterations in which a particular treatment is cost-
effective provides an estimate of the probability of cost-
effectiveness.15
Missing data were handled using multiple imputation
(MI) methods.16 MI using chained equations was
applied to drug costs, costs for each of the self-reported
resource use questions, institutionalization costs, and the
EQ-5D utility score using predictive mean matching.
Forty imputed data sets were created and averaged using
Rubin’s rule.17 Included as covariates in the imputation
equations were patients’ baseline characteristics (age and
sex), health outcomes, and health status measures
(dementia, motor complications, and Hoehn and Yahr
score), and a 1-period lagged value of the outcome vari-
able. Imputation was performed separately by treatment
allocation at randomization in accordance with guideline
recommendations.18 Two-part models were used for all
cost items owing to the high frequency of zero observa-
tions. The probability of positive costs was estimated in
the first part and the cost conditional on observing posi-
tive costs in the second, and from these expected cost
was computed.19 Predicted costs and QALYs for the
period in which death occurred were adjusted for the
proportion of the year survived.
To assess whether the differences in total costs and
QALYs between levodopa and levodopa-sparing thera-
pies differed for individuals older and younger than
70 years, an age effect and an interaction with treat-
ment allocation were included in the linear regression
models.
TABLE 2 QALYs and costs over mean 4 years of follow-up by treatment allocation and differences for the levodopa versus levodopa-sparing comparison
Levodopa Levodopa-sparing Differencea
Quality-adjusted life-years
Unadjusted 2.27 (0.05) 2.10 (0.04) −0.17 (−0.30 to −0.04); P = 0.01
Adjusted −0.18 (−0.30 to −0.05); P < 0.01
Costs (UK 2011 £)
Levodopa 493 (15) 307 (11) −186 (−223 to −150); P < 0.01
Dopamine agonists 1107 (187) 3879 (146) 2773 (2308 to 3238); P < 0.01
MAOBIs 89 (25) 294 (20) 206 (143–268); P < 0.01
Other drugs 207 (23) 144 (17) −63 (−120 to −6); P = 0.03
Drug subtotals 1896 (194) 4624 (151) 2729 (2248–3210); P < 0.01
Primary care and outpatient use 3187 (185) 3848 (145) 661 (193–1130); P < 0.01
Inpatient and respite care 9442 (2918) 6991 (1955) −2452 (−9032 to 4129); P = 0.46
Personal social services 4561 (641) 4965 (482) 403 (−1192–1999); P = 0.62
Institutionalization 2675 (532) 3177 (402) 502 (−807–1811); P = 0.45
Total costsb 5083 (287) 8473 (225) 3390 (2671–4109); P < 0.01
Values are mean (standard error) or mean (95% confidence interval).
aPositive values indicate higher costs and higher QALYs for those allocated levodopa-sparing.
bIncludes only those cost components for which there is a significant difference (P < 0.05) between arms.
MAOBI, monoamine oxidase type B inhibitor.
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In the primary analysis, costs were attached to each
drug based on the observed drug within each class (ie,
levodopa, DA, MAOBI). However, the costs of drugs
within class differ substantially, and there is no evi-
dence of differential effectiveness by drug. Sensitivity
analyses were therefore undertaken to explore the
impact of using the cheapest drug within each class on
cost-effectiveness (ie, ropinirole for patients receiving
DA and oral selegiline for patients receiving MAOBI),
assuming the choice of drug within class had no effect
on HRQoL.
Results
One thousand six hundred and twenty people with
early-stage PD were assigned to treatment groups in PD
MED. The 27 individuals recruited in the Czech
Republic or Russia were excluded from this analysis.
Of the remainder, 1057 (66%) were randomly assigned
3 ways among DA, MAOBI, and levodopa, 335 (21%)
were assigned 2 ways between DA and levodopa, and 201
(13%) were assigned 1 ways between DA and MAOBI. In
total 1392 were randomized between levodopa-sparing
therapy and levodopa and 905 between the 2 levodopa-
sparing therapies, DA and MAOBI. Patients assigned only
between DA and MAOBI had less severe disease and
higher HRQoL and were younger than those in other
assignations. Baseline EQ-5D utility was higher for those
assigned MAOBI than for those assigned DA (0.68 vs
0.65; P for difference = 0.03). Other patient characteristics
were balanced between randomization and treatment
groups (Table 1). Rates of withdrawal (n = 33) and loss to
follow-up (n = 5) were low; most censoring was because of
the end of trial follow-up. The percentages of missing data
in each year were similar across different types of resource
FIG. 1. Cost-effectiveness scatterplots for (A) levodopa versus levodopa-sparing and (B) dopamine agonists versus MAOBIs. (A) Levodopa versus
levodopa-sparing. (B) Dopamine agonists versus MAOBIs. The gray circle represents the joint estimated distribution of cost and quality-of-life differ-
ences between treatment allocations based on 2000 bootstrapped samples. The black circle gives means of these differences.
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use and HRQoL and increased with follow-up time
(Table S2).
Levodopa Versus Levodopa-Sparing
The mean follow-up time in the comparison of levo-
dopa versus levodopa-sparing was 4 years. Total QALYs
were higher among those allocated levodopa (2.27 ± 0.05
QALYs) than those allocated levodopa-sparing therapy
(2.10 ± 0.04 QALYs), and the unadjusted difference of
0.17 QALYs (95% CI, 0.04–0.30 QALYs; P = 0.01) was
significant. Adjusting for QALYs at recruitment had little
effect on the difference (0.18 QALYs; 95% CI, 0.05–0.30
QALYs; P < 0.01); see Table 2.
The mean aggregate cost of levodopa therapy received
over the mean 4 years of follow-up was £186 (95% CI,
£150–£223; P < 0.01) higher among those allocated levo-
dopa than those allocated levodopa-sparing therapies.
The costs of DAs and MAOBIs were higher among those
allocated levodopa-sparing therapies than those allocated
levodopa, with differences of £2773 (£2308–£3238;
P < 0.01) and £206 (£143–£268; P < 0.01), respectively.
The cost of other drugs received was higher among those
allocated levodopa (£63; 95% CI: £6–£120; P = 0.03). In
total, drug costs were £2729 (£2248–£3210; P < 0.01)
higher in those allocated levodopa-sparing therapies com-
pared with those allocated levodopa. Mean incremental
costs for primary and outpatient care were £661 (£193–
£1130; P < 0.01) higher among those allocated levodopa-
sparing therapies. There was no evidence of significant
differences in costs of inpatient care, home care, or in
institutional care between treatment arms. Including
drug costs and outpatient care costs, mean aggregate
costs were £3390 (£2671–£4109; P < 0.01) higher
among those allocated levodopa-sparing therapies
(Table 2).
Allocation to levodopa was associated with sig-
nificantly higher mean QALYs and lower mean costs
than levodopa-sparing therapies. The probability that
levodopa is cost-effective was estimated at 100% for all
threshold values for a QALY considered (Fig. 1A).
There was no evidence that the costs (P for interac-
tion = 0.32), QALYs (P = 0.80), or cost-effectiveness
differed for individuals younger than 70 years. Assum-
ing all patients receiving DA and MAOBI receive
ropinirole (mean daily dose, 11.4 mg) and oral
selegiline (mean daily dose, 8.3 mg), respectively, the
mean cost difference between levodopa and levodopa-
sparing therapy fell by £876 to £1853, but still favored
levodopa. Comparing levodopa with only MAOBI,
assuming all patients received oral selegiline, the differ-
ence was smaller (£571) but still favored levodopa. This
difference reflects greater treatment switching to DAs
among those allocated MAOBIs than among those
allocated placebo.1 Hence, cost-effectiveness is not
materially affected by the use of the least costly
levodopa-sparing therapies, even assuming no differ-
ence in effectiveness between drugs within class.
TABLE 3 QALYs and costs over mean 4 years of follow-up by treatment allocation and comparison of differences for dopamine agonists versus MAOBIs
Dopamine agonists MAOBI Differencea
Quality-adjusted life-years
Unadjusted 2.11 (0.06) 2.14 (0.06) 0.03 (−0.13 to 0.19); P = 0.71
Adjusted −0.02 (−0.17 to 0.13); P = 0.79
Costs (UK 2011 £)
Levodopa 302 (16) 285 (15) −16 (−60 to 27); P = 0.46
Dopamine agonists 5620 (245) 2793 (244) −2827 (−3507 to −2148); P < 0.01
MAOBI 57 (31) 652 (32) 595 (507–684); P < 0.01
Other drugs 172 (22) 109 (21) −63 (−123 to −3); P = 0.04
Durg subtotals 6151 (253) 3840 (252) −2311 (−3014 to −1609); P < 0.01
Primary care and outpatient use 3759 (201) 3700 (198) −59 (−612 to 493); P = 0.83
Inpatient and respite care 6809 (2516) 7039 (2514) 230 (−6715 to 7175); P = 0.95
Personal social services 4516 (640) 4014 (616) −502 (−2260 to 1255); P = 0.58
Institutionalization 2370 (546) 2850 (544) 479 (−1039 to 1998); P = 0.54
Total costsb 5849 (250) 3554 (249) −2295 (−2989 to −1601); P < 0.01
Values are mean (standard error) or mean (95% confidence interval).
aPositive values indicate higher costs and higher QALYs for those allocated MAOBIs.
bIncludes only those cost components for which there is a significant difference (P < 0.05) between arms.
MAOBI, monoamine oxidase type B inhibitor.
6 Movement Disorders, 2021
M C I N T O S H E T A L
DA versus MAOBI
Mean follow-up time in the comparison of DA versus
MAOBI was 4 years. Mean QALYs were similar for
those allocated MAOBIs (2.14 ± 0.06) and DA (2.11
± 0.06), with a nonsignificant difference of 0.03 QALYs
(95% CI, −0.13 to 0.19 QALYs; P = 0.70). Adjusting
for baseline QALYs, the difference (−0.02 QALYs;
95% CI, −0.17 to 0.13 QALYs; P = 0.79) remained
nonsignificant (Table .3).
Mean aggregate costs of DA were £2827 (95% CI,
£2148–£3507; P < 0.01) higher for those allocated DA
than for those allocated MAOBI. Costs for MAOBIs were
£595 (95% CI, £507–£684; P < 0.01) higher amongst
those allocated to the MAOBI arm. There was no signifi-
cant difference in the costs of levodopa between arms
(P = 0.46). Costs of other drugs were higher among those
allocated DA (difference, £63; 95% CI, £3–£123;
P = 0.04). There were no significant differences in costs
for primary care and outpatient care, hospital admissions,
personal social services, or institutional care. Including
those components of costs for which there were signifi-
cant differences between arms, total costs were £2295
(95% CI, £1601– £2989; P < 0.01) higher for those allo-
cated DA (Table .3).
Allocation to MAOBIs was associated with significantly
lower costs than allocation to DAs, with no evidence of a
difference in QALYs. For UK threshold values of £20,000
and £30,000 per incremental QALY, the probability that
allocation to MAOBI is cost-effective compared with DA
was 92% and 81%, respectively (Fig. 1B). Assuming all
patients on DA receive ropinirole and all patients on
MAOBI receive oral selegiline, the mean cost difference
between DA and MAOBI remains very similar at £2133,
favoring MAOBI. Hence, MAOBI remains the more cost-
effective option even when compared with using the least
costly DA.
Discussion
Allocation to levodopa was found to slightly improve
HRQoL and reduce health care costs relative to allocation
to the more expensive levodopa-sparing therapies. Levo-
dopa is therefore deemed to be a highly cost-effective alter-
native to levodopa-sparing therapies. These results are
consistent with themain clinical results, which reported bet-
ter patient-rated HRQoL in the short- and long term with
allocation to levodopa despite these patients developing
more involuntarymovements.1
The higher cost of levodopa-sparing therapy was pre-
dominantly a result of the high costs of DA. Assuming
patients allocated to DAs and MAOBIs used the lowest-
cost drug within class with no detrimental impact on
quality of life, levodopa remained the cost-effective
option. However, the rate of treatment switching from
MAOBIs to DAs observed in this study is likely to be
lower in current clinical practice following the results of
the PD MED trial; this would further reduce the cost dif-
ference between levodopa andMAOBI therapies.
Previous analyses of PD MED identified a small advan-
tage of MAOBIs over DAs in PDQ-39 mobility and sum-
mary index scores, but no significant difference in EQ-5D
utility value.1 Our area under the curve analyses similarly
identified no difference in QALYs between levodopa-
sparing treatment arms. However, because DAs are sub-
stantially more costly than MAOBIs, treatment with
MAOBIs is the cost effective option when treatment with
levodopa is not considered appropriate.
In clinical practice, patients younger than 60 years are
typically initially treated with either a DA or MAOBI to
avoid levodopa-related motor complications. Levodopa
tends to be used in patients older than 70 years for whom
long-term complications are judged to be less important.
However, the PD MED clinical article identified no differ-
ence in treatment efficacy in those younger and older than
70 years. Similarly, no evidence was found in these analyses
for a difference in QALYs, costs, or cost-effectiveness
between age groups. However, the incidence of PD among
individuals younger than 60 years is low,2,20 and only 12%
of patients in PD MED and fewer in the levodopa versus
levodopa-sparing comparison were younger than 60 years
at randomization. Further research — including longer
follow-up of PD MED — is therefore needed to assess any
age-related differences with greater certainty.
Resource use information across broad-ranging health
and PSS was collected using self-reported questionnaires,
raising the possibility of measurement error and leading
to a substantial amount of missing data. Missingness was
not related to treatment allocation but was found to be
related to onset of dementia. Because dementia is likely to
be an important cost driver, reported costs for use of
health care services may underestimate true costs. How-
ever, differences in rates of dementia were not significantly
different between treatment arms. Indeed, observed differ-
ences favored levodopa and so would be unlikely to con-
tradict the conclusions of this analysis. Similarly because
of the self-reported nature of resource use, costs in the
period prior to death are likely to be underestimated;
however, there is a nonsignificant difference in mortality
favoring levodopa, so any bias is not expected to materially
affect the conclusions. Further work is required to assess
the extent of any bias resulting from inaccuracies in patient
self-reported resource use, although we would expect any
such bias to have equal effects across randomized treatment
arms. Following NICE guidance,10 we have not taken into
account locally negotiated price discounts that may reduce
the list price of some of the therapies considered here. Nor
havewe included costs other than those falling on the health
and PSS systems, for example, patient and family expendi-
ture on institutional care.
A further potential limitation of PD MED was the
use of open-label treatment, which could have
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promoted assessment bias. However, any such bias is
probably small because all patients received active
treatment and might also be likely to favor levodopa-
sparing therapy insofar as the clinical results of PD
MED were counter to the a priori expectations of most
clinicians and patients. In comparing classes of drugs,
we assumed equal efficacy of drugs within class in the
absence of data to the contrary. Future assessments of
cost-effectiveness between classes of drugs would bene-
fit from further head-to-head comparisons between
agents within each class.
In conclusion, allocation to levodopa was found to
be associated with higher QALYs and reduced costs
compared with allocation to levodopa-sparing thera-
pies. Furthermore, if levodopa-sparing therapy is used,
MAOBI therapy might be preferred, as it was associated
with similar QALYs but substantially reduced costs.
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